Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter.

Gao P, Zhou GY, Guo LL, Zhang QH, Zhen JH, Fang AJ, Lin XY

Department of Pathology, School of Medicine, Shandong University, Jinan 250012, China. gaopeng@sdu.edu.cn

Multidrug resistance (MDR) is a serious obstacle for cancer chemotherapy. The aim of this study was to reverse MDR of breast carcinoma cells specifically by degrading mdr1 mRNA with anti-mdr1 ribozyme. Our strategy was to limit the expression of ribozyme to only breast-derived cells, but not other type of cells. The results showed the recombinant ribozyme pEGFP-RZmuc was expressed in two kinds of breast carcinoma cells, but not in non-breast-derived cancer cells. Evaluation of chemosensitivity showed that a 15-fold reduction in drug resistance for Adriamycin and a 32-fold reduction in drug resistance for Vinblastine were observed in the transfected cells. Our results demonstrate the efficacy and selectivity of pEGFP-RZmuc to reverse MDR in drug resistant breast carcinoma cells in vitro.

Published 5 September 2007 in Cancer Lett, 256(1): 81-9.
Full-text of this article is available online (may require subscription).

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.